Logo Annals of Transplantation Logo Annals of Transplantation Logo Annals of Transplantation

Generic products – requirements for drug registration

P. K. Kunicki

Ann Transplant 2008; 13(1): 30-30 :: ID: 880184


European Regulatory Agencies e.g. EMEA define what generic product is. It is a medicinal product essentially similar to an original product i.e. which has the same qualitative and quantitative composition in active substances, the same pharmaceutical form, and whose bioequivalence with the reference product has been demonstrated by appropriate bioavailability studies. It means that generic should be almost identical to an innovator product and everyone knows it is almost impossible. Therefore, precise quantitative criteria are necessary to set the borderline for dissimilarity that could be accepted regarding drug safety and efficacy. The majority of generics of generally acting drugs require for registration purposes bioequivalence studies thus this is statistical acceptance for bioavailability parameters what creates the door onto a market. The simplest study design is: single dose, 2-period, 2-sequence, crossover bioequivalence study in young (18-55 y.) healthy volunteers in fasting state, if necessary the design becomes more complex including food effect testing and multiple dosing. In general, Registration Agencies require for proving average bioequivalence, 90% confidence intervals for AUC and Cmax ratios (test/reference) within 0.80-1.25 for log-transformed data. That means generic product is acceptable differing up to 20% from the reference product in 90% of subjects. That door seems to be too wide for a few percent of drugs which are "narrow therapeutic index" and/or "critical dose" drugs. It is obvious that because of clear economic reasons, the manufacturer introducing generic drug is doing only what is necessary for successful registration of the product i.e. the simplest, the shortest and the cheapest study. Such a situation may provoke the collision of interest between patient's safety and interest of generic companies. Therefore the task for Registration Agencies is to create and to obey clear rules for introducing generic products on the market taking into account that bioequivalence requirements must be related to specifi c drug.

Keywords: intellectual disability (mental retardation), Metabolism syndrome, Transplantation


In Press

06 May 2022 : Original article  

Phosphatidylethanol (PEth) for Monitoring Sobriety in Liver Transplant Candidates: Preliminary Results of D...

Ann Transplant In Press; DOI: 10.12659/AOT.936293  

27 Apr 2022 : Review article  

A Systematic Review of the Literature on Chronic Kidney Disease Following Liver Transplantation

Ann Transplant In Press; DOI: 10.12659/AOT.935170  

Most Viewed Current Articles

31 Dec 1969 : Original article  

Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...

DOI :10.12659/AOT.933588

Ann Transplant 2021; 26:e933588

31 Dec 1969 : Review article  

Recurrence of Hepatocellular Carcinoma After Liver Transplantation: Risk Factors and Predictive Models

DOI :10.12659/AOT.934924

Ann Transplant 2022; 27:e934924

31 Dec 1969 : Review article  

Kidney Transplantation in the Times of COVID-19 – A Literature Review

DOI :10.12659/AOT.925755

Ann Transplant 2020; 25:e925755

31 Dec 1969 : Case report  

Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...

DOI :10.12659/AOT.935860

Ann Transplant 2022; 27:e935860

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Annals of Transplantation eISSN: 2329-0358
Annals of Transplantation eISSN: 2329-0358